JVZ-007 was constructed with the CD28 transmembrane, co-stimulatory domain and CD3ζ signaling domain, which responded to PSMA+ tumor cells, LNCaP and DU-145, by inducing IL2 and INF-γ secretion and increasing CD69 expression. Here, IL2 is linked to neoplasm.